{"url_path":"/sec/eltp/10-k/2026/item-9b","section_key":"item-9b","section_title":"Item 9B OTHER INFORMATION**.","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1053369/0001493152-26-031070-index.html","accession_number":"0001493152-26-031070","cik":"0001053369","ticker":"ELTP","issuer_name":"ELITE PHARMACEUTICALS INC /NV/","edgar_url":"https://www.sec.gov/Archives/edgar/data/1053369/0001493152-26-031070-index.html","primary_entity_key":"0001053369","primary_entity_name":"ELITE PHARMACEUTICALS INC /NV/"},"word_count":65,"has_tables":true,"body_markdown":"**Item\n9B. OTHER INFORMATION**.\n\n** **\n\nDuring\nthe fiscal year ended March 31, 2026, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Securities\nExchange Act of 1934, as amended) adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as\nsuch terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933, as amended)."}